Business Context and Reporting Period
This Form 8-K, filed on September 7, 2025, by IDEAYA Biosciences, Inc. (IDYA), reports "Other Events" (Item 8.01) regarding the presentation of positive clinical data for three key therapeutic candidates. The data were presented at the IASLC 2025 World Conference on Lung Cancer and the Company's 10-Year Anniversary R&D Day. The reporting covers data cut-off dates ranging from May 23, 2025, to August 29, 2025.
Key Clinical Metrics and Financial Status
Financial Metrics: The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. This is a current report focused on clinical milestones rather than financial results.
Clinical Metrics:
- IDE849 (DLL3 TOP1 ADC) in Small Cell Lung Cancer (SCLC): In 71 evaluable patients (2L+), the Overall Response Rate (ORR) was 73.2% (52/71) and Disease Control Rate (DCR) was 93.0% (66/71). Median Progression-Free Survival (PFS) was 6.7 months across all lines; not reached in 2L patients. In patients with baseline brain metastases (n=18), confirmed ORR was 66.7% with 100% DCR.
- Darovasertib (PKC Inhibitor) in Uveal Melanoma: In 21 efficacy-evaluable patients, 76% achieved ≥20% ocular tumor shrinkage. 48% achieved ≥20% reduction in simulated radiation dose to key visual structures. 65% observed visual improvement (median 6 letters gained).
- IDE397 + Trodelvy (MAT2A Inhibitor + ADC) in Urothelial Cancer: In 16 evaluable patients with MTAP-deletion, ORR was 33% at Dose Level 1 and 57% at Dose Level 2. DCR was 100% at DL1 and 71% at DL2. Median PFS and duration of response were not reached.
Material Changes and Developments
The filing details significant clinical advancements compared to prior periods:
- IDE849: Initial Phase 1 data presented for a potential first-in-class ADC in SCLC, showing robust efficacy in heavily pre-treated patients and those with brain metastases.
- Darovasertib: Positive interim Phase 2 data demonstrated tumor shrinkage and reduced radiation requirements in the neoadjuvant setting. The Phase 3 registration-enabling OptimUM-10 trial was initiated in Q2 2025.
- IDE397: Initial Phase 1/2 combination data presented for MTAP-deletion urothelial cancer. First patient in for the MTAP NSCLC combination cohort was achieved in Q3 2025.
Outlook, Risks, and Management Commentary
Outlook and Next Steps:
- IDE849: Data suggests a manageable safety profile; further updates expected as data matures.
- Darovasertib: Additional data from over 90 patients in the OptimUM-09 trial will be presented at ESMO (October 17-21, 2025).
- IDE397: Selection of the recommended Phase 2 dose is targeted for end of 2025, with the next update planned for a medical conference in H1 2026.
Risks and Contingencies:
- Safety: For IDE849, Grade 3+ treatment-related adverse events (TRAEs) occurred in 48% of patients; interstitial lung disease was reported in 7% (1% Grade 3). For Darovasertib, 10% of patients experienced Grade 3+ TRAEs, with 4 discontinuations. For IDE397, safety was consistent with known profiles of single agents.
- Forward-Looking Statements: The filing includes standard warnings regarding uncertainties in drug development, regulatory approval, manufacturing, and intellectual property. The Company undertakes no obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the maturity of the IDE849 data, noting that 14.1% of responses are pending confirmation and median follow-up was only 3.5 months.
- Confirm the enrollment and progress of the Phase 3 OptimUM-10 trial for darovasertib initiated in Q2 2025.
- Monitor the selection of the recommended Phase 2 dose for IDE397, targeted for end of 2025.
- Review the safety profile of IDE849, specifically the 48% rate of Grade 3+ TRAEs and 7% incidence of interstitial lung disease.
- Check for upcoming presentations at ESMO (October 2025) for darovasertib and H1 2026 for IDE397.